We discovered, characterised and commercialised Macrophage inhibitory cytokine-1 (MIC-1/GDF15) for human therapy. Its blood level predicts death from cancer, heart attack/stroke and other diseases. This study will add important information for understandg the actions of this important protein
Understanding Ligand Binding Within The Insulin-like Growth Factor Family With Direct Application To Cancer Therapeutic Design
Funder
National Health and Medical Research Council
Funding Amount
$861,235.00
Summary
Cancer is a devastating disease and there is an imperative to develop new therapeutics. The so-called insulin-like growth factors are molecules that play a key role in the initiation and progression of cancer. Here we seek to understand how these molecules interact with cells and to develop drugs that might block their action.
In 2011 there were over 360 million people with type 1 and type 2 diabetes worldwide, who will require insulin treatment. There is an urgent need for insulin analogues that provide effective control of blood glucose to avoid unwanted hypoglycemic or hyperglycemic events. We have developed two novel insulin analogues with unique properties and aim to understand their mechanism of action. This knowledge will present new opportunities for improved insulin mimetics for diabetes treatment.
Structural Events In Insulin And IGF Signalling - A Nanodisc Approach To A Problem In Cancer, Diabetes And Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$752,403.00
Summary
Insulin and its insulin-like growth factors play a major role in three major disease states facing ageing Australians—diabetes, cancer and Alzheimer's disease. We aim to understand how these proteins send messages into cells via their so-called receptors. We will isolate the receptor molecules from cells and then image them in an advanced electron microscope to produce three-dimensional images. Our findings will have implications for the design of therapeutics targeting the above three diseases.
Conformational Change In Insulin And Type I Insulin-like Growth Factor Receptor Upon Ligand Binding
Funder
National Health and Medical Research Council
Funding Amount
$415,365.00
Summary
Insulin and insulin-like growth factors bind to receptor molecules on the surfaces of cells. The binding event results in a signal being sent into the cell to initiate in the case of insulin, uptake of glucose into the cell and, in the case of the growth factors, normal human growth. Breakdown of these processes is implicated in a number of disease states, including diabetes, cancer and Alzheimer's disease. This Project aims to decipher the receptor triggering mechanism that is responsible for g ....Insulin and insulin-like growth factors bind to receptor molecules on the surfaces of cells. The binding event results in a signal being sent into the cell to initiate in the case of insulin, uptake of glucose into the cell and, in the case of the growth factors, normal human growth. Breakdown of these processes is implicated in a number of disease states, including diabetes, cancer and Alzheimer's disease. This Project aims to decipher the receptor triggering mechanism that is responsible for getting the signal into the cell.Read moreRead less
Cancer Anorexia/cachexia: Mechanisms For Anorexia And Appetite Regulation By Tumour Derived MIC-1/GDF15
Funder
National Health and Medical Research Council
Funding Amount
$643,060.00
Summary
We have recently discovered that MIC-1 is a new appetite suppressive agent which when overproduced in some diseases like cancer, causes severe weight loss. This project sets out to determine the mechanisms it employs in regulation of appetite centres in the brain.
Targeting The Insulin And Insulin-like Growth Factor Receptors In Cancer, Diabetes And Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$993,251.00
Summary
Diabetes, cancer and Alzheimer's disease are three major diseases facing Australia. This Project will investigate a common point-of-focus of these diseases, namely the interaction of insulin and the insulin-like growth factors with their receptor molecules on the cell surface. It will use recent breakthrough findings by the Chief Investigators to develop new therapeutic approaches for these diseases that could function by targeting these interactions.
Intervention To Reduce The Risk Of Diabetic Retinopathy And Early Adverse Retinal Changes In Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$1,294,846.00
Summary
The long term effects of young onset T1D may be devastating: diabetes is the leading cause of visual loss in young adults in Australia and other countries. We have the unique opportunity to investigate whether ACEI and statins will modify retinopathy through our collaboration with an already funded international multicentre trial. This study will treat adolescents for 4 years and will follow them for the next 5-10 years. We will use novel measures of retinal blood vessels size and fractals.
Epigenetic Mechanisms Of Dysregulated Immune Function In Autoimmune And Allergic Disease Of Childhood
Funder
National Health and Medical Research Council
Funding Amount
$452,298.00
Summary
The rising incidence of autoimmune and allergic diseases is ascribed to the environment, which can modify the chemistry of DNA and how our genes work (epigenetics). We aim to identify epigenetic changes in immune cells in infants at risk for type 1 diabetes and food allergy followed from birth. This may reveal both general and disease-specific levels of epigenetic-immune dysregulation and is a foundation on which to understand potentially modifiable environment-gene interactions.
Free-Living Closed-Loop Insulin Delivery For Patients With Type 1 Diabetes: A Long-term Multi-centre Randomized Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,041,986.00
Summary
Closed loop technology for automating the delivery of insulin to patients with Type 1 diabetes has the potential to improve the lives of many with the disease. Though early prototypes are currently under evaluation in small studies, no studies have yet to date applied the technology in a large scale randomised trial. We propose to undertake such a study in order to demonstrate the utility of this technology and facilitate its eventual routine and widespread use in the community in the future.